The EveryPrem Project: Evaluating the INTER-NDA for Standardized Neurodevelopmental Screening at 2 Years of Age for Children Born Preterm.

NCT ID: NCT05065385

Last Updated: 2021-10-04

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 800 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-11-01
• Study Completion Date: 2025-12-31

Brief Summary

Neurodevelopmental follow-up of infants at high-risk such as preterm born is necessary in order to early detect impairments and early start a supportive/therapeutic intervention. Valid tools should be available for screening infants with developmental problems even where resources are limited. Such screening would ensure an adequate medical care during and after hospital discharge as well as evidence-based parental pre- and postnatal counselling. While in Switzerland, these tools are specifically needed for the neurodevelopmental surveillance of moderate to late pretem born infants, in low- and mid-income countries, they are needed to monitor the whole population of preterm born infants.

To fill this important gap, the present study aims to determine whether it is feasible to extend neurodevelopmental screening (currently offered to only a very small part of children born preterm), by using a new cost-effective neurodevelopmental assessment, the INTERGROWTH-21st Neurodevelopment Assessment (INTER-NDA, www.inter-nda.com Assessment) at age 2 years.

Detailed Description

The pirmary objectives of the study are:

1. In very preterm born infants (born < 32 weeks' gestation)

• To assess the concurrent validity of the INTER-NDA with the Bayley-III[13] at 2 years of corrected age in VPT infants.

2. In moderate to late preterm infants (born between 32 and 36 weeks' gestation) - To screen neurodevelopment performances at corrected 2 years of corrected age in MLPT infants by means of the INTER-NDA and to compare values with international INTER-NDA standard values.

Conditions

Prematurity

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Interventions

INTER-NDA

Neurodevelopmental Screening Test at age 2 years.

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

Bayley Scales of Infant and Toddler Development, 3rd Edition

Eligibility Criteria

Inclusion Criteria

• Former patient of the Department of Neonatology of the University Hospital Zurich
• Born between 01.01.2019 and 31.12.2021, i.e. aged 18 to 30 months at the time of the research visit
• Gestational age below 370/7 weeks
• Parent consent

Exclusion Criteria

• Genetically defined syndrome (including chromosomal aberration) or inborn error of metabolism adversely influencing life expectancy or neurodevelopment.
• Major congenital malformations requiring surgical correction or potentially affecting neurodevelopmental outcome.
• Hypoxic ischemic encephalopathy after perinatal asphyxia defined as grade 2 or 3 according to Sarnat and Sarnat[19].
• Neonatal drug withdrawal syndrome or known maternal substance consumption of following illicit drugs during pregnancy: cocaine, heroin, Lysergic acid diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (ecstasy), phencyclidine (PCP), and other amphetamine/methamphetamine.
• Children of parents who are not speaking German

• Minimum Eligible Age: 18 Months
• Maximum Eligible Age: 30 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Giancarlo Natalucci

OTHER

Sponsor Role: lead

Responsible Party

Giancarlo Natalucci

Prof. Dr. med.

Responsibility Role: SPONSOR_INVESTIGATOR

Central Contacts

Giancarlo Natalucci, MD

Role: CONTACT

giancarlo.natalucci@usz.ch

+41 44 255 53 86

Other Identifiers

BASEC 2020-02598

Identifier Type: -

Identifier Source: org_study_id